首页> 外文期刊>Cancer control : >Evaluation of Tumor Budding in Predicting Survival for Gastric Carcinoma Patients in Vietnam
【24h】

Evaluation of Tumor Budding in Predicting Survival for Gastric Carcinoma Patients in Vietnam

机译:肿瘤芽预测越南胃癌患者存活的评价

获取原文
       

摘要

Background: Tumor budding (Bd) has been demonstrated to be a promising prognostic factor in many carcinomas and in gastric cancer. It may represent an optimal additional parameter that is helpful for risk stratification in gastric adenocarcinoma. Hence, the present research was designed to predict the survival outcomes of gastric cancer in Vietnam, applying the tumor budding criteria of the International Tumor Budding Consensus Conference (ITBCC) 2016. Methods: The present study was conducted on 109 gastric cancer patients who underwent surgery but did not receive neo-adjuvant chemotherapy from 2012 to 2015. The patients’ clinicopathological features were recorded. Bd was evaluated according to the 2016 ITBCC criteria and classified as Bd1 (0–4 buds), Bd2 (5–9 buds), and Bd3 (≥10 buds) grades, in addition to being categorized into 2 main Bd groups: low (10 buds) and high (≥10 buds) Bd. Kaplan–Meier and log-rank models were applied to analyze survival proportions. Results: Of all the patients, 22.9% were classified as Bd1, 31.2% as Bd2, and 45.9% as Bd3 grades. Furthermore, 54.1% patients were categorized into the low and 45.9% into the high Bd groups. Patients with Bd1 and Bd2 grades (the low Bd group) exhibited the best prognosis, with 5-year overall survival (OS) rates of 85.7%, 90.8%, and90.3%, respectively. Patients with Bd3 grade (the high Bd group exhibited the worst prognosis, and none of them lived for 5 years (p 0.001). Similar to OS rates, disease-free survival (DFS) rates markedly reduced from the Bd1 to Bd3 grade: Bd1, 95.0%; Bd2, 84.7%; and Bd3, 0% (p 0.001). Conclusion: Patients with different gastric cancer Bd grades exhibited significantly different OS and DFS rates. The present study findings suggest that the ITBCC criteria can be used to stratify Bd for the treatment and prognosis of gastric cancer patients in Vietnam.
机译:背景:肿瘤芽(BD)已被证明是许多癌症和胃癌中的有希望的预后因素。它可以表示有助于胃腺癌中的风险分层有用的最佳附加参数。因此,本研究旨在预测越南胃癌的存活结果,应用国际肿瘤崭露头角协商会议(ITBCC)2016年的肿瘤萌芽标准。方法:本研究是对接受手术的109例胃癌患者进行但从2012年到2015年没有接受新辅助化疗。记录患者的临床病理学特征。根据2016年的ITBCC标准评估BD,并归类为BD1(0-4芽),BD2(5-9个芽)和BD3(≥10芽)等级,除了分为2个主要的BD组:低( <10芽)和高(≥10芽)BD。应用Kaplan-Meier和日志排名模型来分析生存比例。结果:在所有患者中,22.9%被归类为BD1,31.2%为BD2,45.9%,为BD3等级。此外,将54.1%的患者分为低BD组,分为低于低调和45.9%。 BD1和BD2等级(低BD组)的患者表现出最佳预后,分别为5年的总生存率(OS)率为85.7%,90.8%,90.3%。 BD3等级(高BD组的患者表现出最差的预后,并且它们都不在5年(P <0.001)。类似于OS率,无病的生存(DFS)率从BD1到BD3等级显着降低: BD1,95.0%; BD2,84.7%;和BD3,0%(P <0.001)。结论:不同胃癌BD等级的患者表现出显着不同的OS和DFS率。目前的研究表明,可以使用ITBCC标准对越南胃癌患者治疗和预后的分层。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号